Profile data is unavailable for this security.
About the company
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-95.31m
- Incorporated2004
- Employees77.00
- LocationImmunic Inc1200 Avenue Of The Americas, Suite 200NEW YORK 10036United StatesUSA
- Phone+49 (8925) 007-9460
- Fax+1 (302) 655-5049
- Websitehttps://imux.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P3 Health Partners Inc | 1.40bn | -69.48m | 153.82m | 400.00 | -- | 0.4169 | -- | 0.1097 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Adverum Biotechnologies Inc | 0.00 | -99.86m | 155.80m | 121.00 | -- | 0.9272 | -- | -- | -7.99 | -7.99 | 0.00 | 8.08 | 0.00 | -- | -- | 0.00 | -40.33 | -36.39 | -46.64 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Achieve Life Sciences Inc | 0.00 | -27.54m | 157.97m | 22.00 | -- | 3.74 | -- | -- | -1.10 | -1.10 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -58.78 | -86.31 | -71.94 | -119.59 | -- | -- | -- | -- | -- | -11.79 | 0.294 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Ventyx Biosciences Inc | 0.00 | -171.30m | 162.54m | 73.00 | -- | 0.5788 | -- | -- | -2.79 | -2.79 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.07 | -- | -55.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Capricor Therapeutics Inc | 27.15m | -27.95m | 164.32m | 101.00 | -- | 14.04 | -- | 6.05 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Immunic Inc | 0.00 | -95.31m | 164.84m | 77.00 | -- | 2.59 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Tenaya Therapeutics Inc | 0.00 | -120.74m | 168.03m | 140.00 | -- | 1.25 | -- | -- | -1.54 | -1.54 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -62.89 | -- | -69.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 591.86k | -121.64m | 168.25m | 122.00 | -- | 1.74 | -- | 284.27 | -5.11 | -5.11 | 0.0248 | 3.73 | 0.0032 | -- | 0.6652 | 4,851.31 | -66.32 | -59.52 | -84.33 | -71.29 | -- | -- | -20,552.24 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Context Therapeutics Inc | 0.00 | -18.57m | 169.50m | 5.00 | -- | 1.68 | -- | -- | -1.06 | -1.06 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -28.46 | -- | -29.68 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 172.19m | 233.00 | -- | -- | -- | 460.40 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Galectin Therapeutics Inc | 0.00 | -48.03m | 172.51m | 14.00 | -- | -- | -- | -- | -0.7831 | -0.7831 | 0.00 | -1.32 | 0.00 | -- | -- | 0.00 | -185.54 | -92.08 | -382.33 | -121.97 | -- | -- | -- | -- | -- | -8.59 | 8.29 | -- | -- | -- | -15.26 | -- | -- | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.90m | 176.55m | 18.00 | -- | 3.30 | -- | -- | -0.5238 | -0.5238 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -33.49 | -45.38 | -34.98 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Lineage Cell Therapeutics Inc | 6.19m | -24.19m | 177.51m | 75.00 | -- | 2.60 | -- | 28.69 | -0.1342 | -0.1342 | 0.0343 | 0.3617 | 0.0577 | -- | 18.25 | 82,480.00 | -22.57 | -19.53 | -26.03 | -22.59 | 90.83 | 89.13 | -391.25 | -370.88 | -- | -- | 0.0017 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Data as of Sep 20 2024. Currency figures normalised to Immunic Inc's reporting currency: US Dollar USD
55.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avidity Partners Management LPas of 30 Jun 2024 | 8.90m | 9.88% |
| BVF Partners LPas of 30 Jun 2024 | 8.90m | 9.88% |
| Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 7.29m | 8.10% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 7.07m | 7.85% |
| Adage Capital Management LPas of 30 Jun 2024 | 5.59m | 6.21% |
| RTW Investments LPas of 30 Jun 2024 | 4.57m | 5.07% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.71m | 4.12% |
| Gratus Capital LLCas of 30 Jun 2024 | 2.11m | 2.34% |
| Geode Capital Management LLCas of 30 Jun 2024 | 936.26k | 1.04% |
| 683 Capital Management LLCas of 30 Jun 2024 | 699.30k | 0.78% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
